Puerto Rico plaintiffs drop Ritalin action

21 August 2001

Attorneys for plaintiffs in a Puerto Rico class action against Novartis,manufacturer of Ritalin (methylphenidate), the American Psychiatric Association and Children and Adults with Attention Deficit/Hyperactivity Disorder, have notified the court that they are dismissing their case against the defendants. Their lawsuit, served in February 2001, had claimed that the defendants conspired to promote the diagnosis of ADHD.

The plaintiffs' decision follows a similar move by such claimants in Florida and dismissed by the courts in lawsuits filed in California (Marketletter March 19) and Texas (Marketletter May 28).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight